Table 2.
Baseline and 12-month follow-up clinical data
| Baseline | Follow-up | p1 | p2 | |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| SCOPA-motor | 30.67 | 8.53 | 30.25 | 10.29 | 0.695 | 0.695 |
| NMSS | ||||||
| Cardiovascular | 2.92 | 3.7 | 2.75 | 3.41 | 0.677 | 0.885 |
| Sleep/fatigue | 14.75 | 10.68 | 13.75 | 7.39 | 0.666 | 0.885 |
| Mood/apathy | 16.75 | 19.26 | 10.08 | 9.98 | 0.028 | 0.252 |
| Perceptual/hallucinations | 1.92 | 3.73 | 2.58 | 5.63 | 0.892 | 0.892 |
| Attention/memory | 11.5 | 10.71 | 9.25 | 6.69 | 0.168 | 0.756 |
| Gastrointestinal | 8.25 | 9.85 | 7.83 | 9.92 | 0.858 | 0.892 |
| Urinary | 10.92 | 8.26 | 10.67 | 9.67 | 0.688 | 0.885 |
| Sexual functioning | 3.27 | 5.31 | 2.33 | 4.66 | 0.450 | 0.885 |
| Miscellaneous | 13.92 | 10.27 | 12.33 | 8.15 | 0.408 | 0.885 |
| Total score | 93.17 | 83.5 | 71.75 | 38.44 | 0.009 | 0.027 |
| PDQ-8 total score | 14.67 | 6.43 | 14.17 | 6.97 | 0.609 | 0.695 |
Data are presented as mean ± standard deviation. Baseline to follow-up changes were tested using the Wilcoxon signed-ranks test. Benjamini–Hochberg procedure was used to correct for multiple testing. A < 0.05 p value was considered statistically significant
SCOPA-Motor SCales for Outcomes in Parkinson's disease, NMSS non-motor symptoms scale, PDQ-8 Parkinson's disease Questionnaire-8, p2 corrected p value